MedTrace Logo

A Phase 1 Study, to Evaluate the Effect of ADV7103 on Gastric pH Under Fed and Fasting Conditions in Adult Healthy Participants.

NCT07446881 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-03-10

No results posted yet for this study

Summary

This was a Phase 1, single-center, randomized, controlled, Latin-square, open-label study to evaluate the effect of ADV7103 on the gastric pH, after administering a single oral dose of ADV7103 in healthy adult participants under fasting and fed conditions

Conditions

  • EFFECT OF ADV7103 ON GASTRIC PH
  • Distal Renal Tublular Acidosis

Interventions

DRUG

ADV7103

EFFECT ON GASTRIC PH

Sponsors & Collaborators

  • Advicenne Pharma

    lead INDUSTRY

Principal Investigators

  • Adrian J Hapner, MD, PhD · Advicenne S.A.

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-25
Primary Completion
2025-03-15
Completion
2025-03-15
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07446881 on ClinicalTrials.gov